Targeting and molecular imaging of HepG2 cells using surface-functionalized gold nanoparticles

Rathinaraj, Pierson; Lee, Kyubae; Choi, Yuri; Park, Soo‐Young; Kwon, Oh Hyeong; Kang, Inn‐Kyu

doi:10.1007/s11051-015-3118-y

Cited by 9 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immortalised hepatic cell lines, normally derived from human hepatocellular carcinoma, have been the "go-to" for researchers for decades for a variety of reasons, including their wide availability from certified cell line sources such as ATCC (i.e., the American Type Culture Collection, which is a non-profit organisation that collects, stores, and distributes standard reference cell lines and other research and development materials), or BIOPREDICT (whose most popular product is the Hep-aRG cell line), relative ease of handling and culture, lack of inter-donor variation [48,[58][59][60], long-term maintenance in culture with a stable phenotype (depending on cell type), and resistance to senescence [61]. For decades, in vitro 2D hepatocyte models have been successfully used to obtain pre-clinical data on many NBMs, including the liposomal forms of irinotecan (including studies undertaken in SK-Hep-1 cells) [62] and doxorubicin (HepG2 cells, among others), gold [63][64][65], SPIONs [66], and carrier NBMs such as poly(alkyl cyanoacrylate) or PACA [67,68] and poly(butyl cyanoacrylate) or PBCA.…”

Section: D Cultures From Immortalised Cell Typesmentioning

confidence: 99%

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials

Tutty

Movia

Prina-Mello

2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Despite the exciting properties and wide-reaching applications of nanobiomaterials (NBMs) in human health and medicine, their translation from bench to bedside is slow, with a predominant issue being liver accumulation and toxicity following systemic administration. In vitro 2D cell-based assays and in vivo testing are the most popular and widely used methods for assessing liver toxicity at pre-clinical stages; however, these fall short in predicting toxicity for NBMs. Focusing on in vitro and in vivo assessment, the accurate prediction of human-specific hepatotoxicity is still a significant challenge to researchers. This review describes the relationship between NBMs and the liver, and the methods for assessing toxicity, focusing on the limitations they bring in the assessment of NBM hepatotoxicity as one of the reasons defining the poor translation for NBMs. We will then present some of the most recent advances towards the development of more biologically relevant in vitro liver methods based on tissue-mimetic 3D cell models and how these could facilitate the translation of NBMs going forward. Finally, we also discuss the low public acceptance and limited uptake of tissue-mimetic 3D models in pre-clinical assessment, despite the demonstrated technical and ethical advantages associated with them. Graphical abstract 3D culture models for use as in vitro alternatives to traditional methods and conventional in vivo animal testing for testing liver accumulation and toxicity of nanobiomaterials

show abstract

Section: D Cultures From Immortalised Cell Typesmentioning

confidence: 99%

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials

Tutty

Movia

Prina-Mello

2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

“…Immortalized hepatocyte cell lines, normally liver epithelial cells derived from human hepatocellular carcinoma, have been the "go-to" for researchers for decades for a variety of reasons, including their wide availability from certi ed sources such as ATCC or BIOPREDICT, relative ease of handling and culture, lack of inter-donor variation [25,[35][36][37], long-term maintenance in culture with a stable phenotype, and resistance to senescence [84]. For decades, in vitro 2D hepatocyte models have been successfully used to obtain preclinical data on many NBMs, including the liposomal forms of Irinotecan (including studies undertaken in SK-Hep-1 cells) [39] and doxorubicin (HepG2 cells, among others) [40], gold [41][42][43], SPIONs [44,45], and carrier NBMs such as Poly(Alkyl Cyanoacrylate, or PACA [46,47] and Poly(Butyl Cyanoacrylate, or PBCA [48]. Despite being widely used as early predictors of NBM liver toxicity in preclinical assessment [21,49], cells lines used in 2D cultures exhibit many disadvantages as presented below.…”

Section: Advantages and Disadvantages Of Existing 2d In Vitro Culture Modelsmentioning

confidence: 99%

“…the American Type Culture Collection, which is a non-pro t organization that collects, stores, and distributes standard reference cell lines and other research and development materials), or BIOPREDICT (whose most popular product is the HepaRG cell line), relative ease of handling and culture, lack of inter-donor variation [25,[35][36][37], long-term maintenance in culture with a stable phenotype, and resistance to senescence [38]. For decades, in vitro 2D hepatocyte models have been successfully used to obtain preclinical data on many NBMs, including the liposomal forms of Irinotecan (including studies undertaken in SK-Hep-1 cells) [39] and doxorubicin (HepG2 cells, among others) [40], gold [41][42][43], SPIONs [44,45], and carrier NBMs such as Poly(Alkyl Cyanoacrylate, or PACA [46,47] and Poly(Butyl Cyanoacrylate, or PBCA [48].…”

Section: Advantages and Disadvantages Of Existing 2d In Vitro Culture...mentioning

confidence: 99%

Three-dimensional (3D) liver cell models - A Tool for Bridging the Gap Between Animal Studies and Clinical Trials When Screening Liver Accumulation and Toxicity of Nanobiomaterials

Tutty

Movia

Prina‐Mello

2022

Preprint

View full text Add to dashboard Cite

Despite the exciting properties and wide-reaching applications in human health and medicine of nanobiomaterials (NBMs), their translation from bench to bedside is slow, with a predominant issue being liver accumulation and toxicity following systemic administration. In vitro 2D cell-based assays and in vivo testing are the most popular and widely used methods for assessing liver toxicity at preclinical stages, however these fall short in predicting toxicity for NBMs. Focusing on the in vitro and in vivo assessment, the accurate prediction of human-specific hepatotoxicity is still a significant challenge to researchers. This review describes such methods, focusing on the limitations they bring in the assessment of NBM hepatotoxicity, as one of the reasons defining the poor translation for NBMs. We will then present some of the most recent advances towards the development of more biologically relevant in vitro liver methods based on tissue-mimetic 3D cell models and how these could facilitate the translation NBM going forward. Finally, we also discuss the low public acceptance and limited uptake of tissue-mimetic 3D models in the pre-clinical assessment, despite the demonstrated technical and ethical advantages.

show abstract

A Glycotherapeutic Approach to Functionalize Biomaterials‐Based Systems

Gadekar

Bhowmick

Pandit

2020

Adv Funct Materials

View full text Add to dashboard Cite

In addition to being one of the primary building block materials of living cells, glycans are also favorable candidates for therapeutic applications. In the mid-20th century, the progress of glycans in the drug discovery field became surpassed by protein and DNA-focused treatments. However, the emergence of new analytical tools and methods to synthesize structurally specific glycans has encouraged and motivated the scientific community toward the development of glycan-based therapeutics. This review discusses the reemergence of glycan-based agents in the last decade and the technical strategies that played a key role in bringing the glycanbased treatments into the limelight of modern medicine. The review also includes the application of native glycans as the therapeutic agents along with the chemically engineered cell surface glycans and proteins to meet the preclinical and clinical scenario. Glycan-based therapeutic materials hold a huge potential that can be harnessed to meet the clinical needs in medicine.

show abstract

Targeting and molecular imaging of HepG2 cells using surface-functionalized gold nanoparticles

Cited by 9 publications

References 41 publications

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials

Three-dimensional (3D) liver cell models - A Tool for Bridging the Gap Between Animal Studies and Clinical Trials When Screening Liver Accumulation and Toxicity of Nanobiomaterials

A Glycotherapeutic Approach to Functionalize Biomaterials‐Based Systems

Contact Info

Product

Resources

About